Ambiq gibt Preisgestaltung für aufgestockten Börsengang bekannt

AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) — Ambiq Micro, Inc. („Ambiq“), ein Technologieführer im Bereich extrem stromsparender Halbleiterlösungen für Edge–KI, hat heute die Preisgestaltung für seine aufgestockte Erstemission von 4.000.000 Stammaktien zu einem öffentlichen Ausgabepreis von 24,00 USD pro Aktie bekanntgegeben. Der Bruttoerlös für Ambiq aus dem Angebot, vor Abzug der von Ambiq zu zahlenden Emissionsrabatte und Provisionen sowie anderer Angebotsaufwendungen, wird voraussichtlich 96,0 Mio. USD betragen. Darüber hinaus hat Ambiq den Konsortialbanken eine 30–tägige Option zum Kauf von bis zu 600.000 zusätzlichen Stammaktien (ausschließlich zur Deckung etwaiger Mehrzuteilungen) zum Erstausgabepreis abzüglich Konsortialrabatten und Provisionen eingeräumt. Die Aktien werden voraussichtlich am 30. Juli 2025 unter dem Tickersymbol „AMBQ“ an der New Yorker Börse zum Handel zugelassen. Der Abschluss der Emission wird vorbehaltlich der Erfüllung der üblichen Abschlussbedingungen für den 31. Juli 2025 erwartet.

BofA Securities und UBS Investment Bank fungieren als gemeinsame leitende Konsortialführer für das Angebot. Needham & Company und Stifel fungieren als gemeinsame Konsortialführer für das Angebot.

Eine Registrierungserklärung bezüglich des Angebots von Wertpapieren wurde am 29. Juli 2025 von der US–Börsenaufsichtsbehörde (Securities and Exchange Commission) für wirksam erklärt. Das Angebot erfolgt ausschließlich mittels eines Verkaufsprospekts. Wenn verfügbar, können Exemplare des endgültigen Prospekts für das Angebot angefordert werden bei: BofA Securities, NC1–022–02–25, 201 North Tryon Street, Charlotte, North Carolina 28255–0001, Attention: Prospectus Department, oder per E–Mail an [email protected] oder UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, telefonisch unter (888) 827–7275 oder per E–Mail an ol–prospectus–[email protected].

Diese Pressemitteilung stellt weder ein Angebot zum Verkauf noch eine Aufforderung zum Kauf dieser Wertpapiere dar, noch darf ein Verkauf dieser Wertpapiere in einem Staat oder einer anderen Rechtsordnung erfolgen, in dem ein solches Angebot, eine solche Aufforderung oder ein solcher Verkauf vor der Registrierung oder Qualifizierung gemäß den Wertpapiergesetzen dieses Staates oder dieser Rechtsordnung unzulässig wäre.

Über Ambiq

Ambiq hat es sich zur Aufgabe gremacht, Intelligenz (künstliche Intelligenz (KI) und darüber hinaus) überall zu ermöglichen, indem das Unternehmen Halbleiterlösungen mit dem geringsten Stromverbrauch bereitstellt. Ambiq ermöglicht es seinen Kunden, KI–Rechenleistung dort bereitzustellen, wo die Herausforderungen hinsichtlich des Stromverbrauchs am größten sind. Die technologischen Innovationen von Ambiq basieren auf der patentierten und proprietären Subthreshold Power Optimized Technology (SPOT®) und bieten eine grundlegende Verbesserung des Stromverbrauchs gegenüber herkömmlichen Halbleiterdesigns. Ambiq hat bis heute über 270 Millionen Geräte mit Strom versorgt.

Zukunftsgerichtete Aussagen

Die in dieser Pressemitteilung enthaltenen Aussagen, die keine historischen Fakten darstellen, sind zukunftsgerichtete Aussagen. Zukunftsgerichtete Aussagen erkennen Sie daran, dass sie Wörter wie „glauben“, „erwarten“, „könnten“, „werden“, „sollten“, „beabsichtigen“, „planen“, „schätzen“ oder „voraussichtlich“ oder ähnliche Ausdrücke enthalten, die sich auf unsere Strategie, Pläne, Prognosen oder Absichten beziehen. Diese zukunftsgerichteten Aussagen können in dieser Pressemitteilung enthalten sein und umfassen unter anderem Aussagen zu den erwarteten Bruttoerlösen von Ambiq aus dem Börsengang, dem voraussichtlichen Datum der Aufnahme des Handels mit Stammaktien von Ambiq an der New York Stock Exchange und dem voraussichtlichen Abschluss des Börsengangs. Zukunftsgerichtete Aussagen sind aufgrund ihrer Eigenschaften keine Aussagen über historische Tatsachen oder Garantien für zukünftige Leistungen und unterliegen Risiken, Ungewissheiten, Annahmen oder Änderungen der Umstände, die schwer vorherzusagen oder zu quantifizieren sind. Die Erwartungen, Überzeugungen und Prognosen von Ambiq werden in gutem Glauben geäußert, und Ambiq ist der Ansicht, dass diese auf einer angemessenen Grundlage beruhen. Es kann jedoch nicht garantiert werden, dass die Erwartungen, Annahmen und Prognosen der Geschäftsführung eintreten oder erreicht werden, und die tatsächlichen Ergebnisse können erheblich von den in den zukunftsgerichteten Aussagen zum Ausdruck gebrachten oder implizierten Ergebnissen abweichen. Alle zukunftsgerichteten Aussagen in dieser Pressemitteilung gelten nur zum Zeitpunkt ihrer Veröffentlichung. Ambiq übernimmt keine Verpflichtung, zukunftsgerichtete Aussagen öffentlich zu aktualisieren oder zu überprüfen, sei es aufgrund neuer Informationen, zukünftiger Entwicklungen oder aus anderen Gründen, es sei denn, dies ist durch geltende Wertpapiergesetze vorgeschrieben.

Kontakt

Charlene Wan 
VP of Corporate Marketing and Investor Relations
[email protected]

Ein Foto zu dieser Mitteilung ist verfügbar unter https://www.globenewswire.com/NewsRoom/AttachmentNg/2b0020d4–b17f–45b8–a173–5f4318a97b59


GLOBENEWSWIRE (Distribution ID 9503548)

Ambiq annonce le prix d’émission de son action dans le cadre de son introduction en bourse élargie

AUSTIN, Texas, 30 juill. 2025 (GLOBE NEWSWIRE) — Ambiq Micro, Inc. (« Ambiq »), leader technologique des solutions de semi–conducteurs ultra–basse consommation pour l’IA de pointe, a annoncé aujourd’hui le prix d’émission de son action dans le cadre de son introduction en bourse élargie portant sur 4 000 000 d’actions ordinaires au prix de 24,00 dollars par action. Pour Ambiq, le produit brut de cette introduction en bourse, avant déduction des commissions et escomptes de prise ferme et autres frais d’émission payables par Ambiq, devrait s’élever à 96 millions de dollars. En outre, Ambiq a accordé aux souscripteurs une option de 30 jours qui leur permettra d’acquérir jusqu’à 600 000 actions supplémentaires (uniquement pour couvrir les éventuelles surallocations) provenant de son capital–actions ordinaire au prix d’introduction en bourse, déduction faite des commissions et escomptes de prise ferme. Les actions devraient être négociées à la Bourse de New York sous le symbole « AMBQ » le 30 juillet 2025, et la clôture de l’offre est prévue pour le 31 juillet 2025, sous réserve du respect des conditions de clôture habituelles.

BofA Securities et UBS Investment Bank interviendront en qualité de co–teneurs de livres principaux pour cette introduction en bourse. Quant à Needham & Company et Stifel, ils interviendront en qualité de co–teneurs de livres.

Une déclaration d’enregistrement relative à l’émission de titres a été déclarée effective par la Securities and Exchange Commission des États–Unis le 29 juillet 2025. L’émission est réalisée uniquement en vertu d’un prospectus. Des exemplaires du prospectus définitif relatif à cette émission pourront être obtenus, dès leur mise à disposition, en contactant : BofA Securities, NC1–022–02–25, 201 North Tryon Street, Charlotte, North Carolina 28255–0001 USA, Attention: Prospectus Department, ou par courriel à l’adresse [email protected], ou en contactant UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019 USA, par téléphone au (888) 827–7275 ou par courriel à l’adresse ol–prospectus–[email protected].

Le présent communiqué de presse ne constitue ni une offre de vente ni une sollicitation d’offre d’achat de ces titres, et aucune vente de ces titres ne sera autorisée dans un État ou une autre juridiction où une telle offre, sollicitation ou vente serait illégale avant dépôt ou éligibilité en vertu des lois de cet État ou de cette autre juridiction relatives aux valeurs mobilières.

À propos d’Ambiq

Ambiq s’est donné pour mission de développer l’intelligence informatique (intelligence artificielle (IA) et au–delà) partout dans le monde en proposant des solutions de semi–conducteurs à faible consommation d’énergie. Ambiq permet à ses clients de déployer des capacités de calcul basé sur l’IA en périphérie de réseau, là où les défis de consommation d’énergie sont les plus importants. Basées sur la technologie brevetée et exclusive d’optimisation énergétique en sous–seuil (SPOT®), les innovations technologiques d’Ambiq permettent d’obtenir une réduction significative de la consommation d’énergie par rapport aux conceptions de semi–conducteurs traditionnelles. À ce jour, Ambiq a alimenté plus de 270 millions d’appareils.

Déclarations prospectives

Les déclarations figurant dans le présent communiqué qui ne relèvent pas de faits historiques constituent des déclarations prospectives. Les énoncés prospectifs sont identifiables par l’utilisation de termes tels que « croit », « s’attend à », « peut », « va », « devrait », « cherche à », « a l’intention de », « projette de », « estime » ou « anticipe », ou d’autres expressions similaires concernant notre stratégie, nos plans, nos projections ou nos intentions. Ces énoncés prospectifs peuvent figurer dans le présent communiqué de presse et incluent, sans s’y limiter, des déclarations relatives au produit brut attendu de l’introduction en bourse d’Ambiq, à la date prévue de cotation des actions ordinaires d’Ambiq à la Bourse de New York et à la clôture prévue de cette introduction en bourse. De par leur nature, les énoncés prospectifs ne constituent pas des déclarations de faits historiques ni des garanties de performances futures, et sont soumis à des risques, incertitudes, hypothèses ou changements de circonstances qui sont difficiles à prévoir ou à quantifier. Les attentes, convictions et projections exprimées par Ambiq le sont de bonne foi, et Ambiq estime qu’elles reposent sur des bases raisonnables. Toutefois, rien ne garantit que les attentes, convictions et projections de la direction se concrétiseront ou seront atteintes, et les résultats réels sont susceptibles d’être sensiblement différents de ce qui est exprimé ou indiqué dans les énoncés prospectifs. Tout énoncé prospectif figurant dans le présent communiqué de presse n’est valable qu’à la date de celui–ci. Ambiq décline toute obligation d’actualiser ou de réviser publiquement tout énoncé prospectif, que ce soit à la suite de nouvelles informations, de développements futurs ou pour toute autre raison, sauf si la législation applicable en matière de valeurs mobilières l’exige.

Coordonnées

Charlene Wan
VP du marketing d’entreprise et des relations avec les investisseurs
[email protected]

Une photo accompagnant le présent communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/2b0020d4–b17f–45b8–a173–5f4318a97b59


GLOBENEWSWIRE (Distribution ID 9503548)

Emaar The Economic City & Al Tahaluf Sign Deal to Deliver New Residential Projects in KAEC’s Al Murooj

KING ABDULLAH ECONOMIC CITY (KAEC), Saudia Arabia, July 30, 2025 (GLOBE NEWSWIRE) — Emaar, The Economic City (EEC), the master developer of King Abdullah Economic City (KAEC), has signed an agreement with Al Tahaluf, a Saudi–American joint venture comprised of a K. Hovnanian subsidiary and the Hamad bin Saedan Real Estate Company, to develop two premium residential communities in the Al Murooj district. The deal reflects a shared ambition to shape a vibrant coastal district and supports KAEC’s goal of attracting high–value development while cementing its position as a lifestyle–led investment destination aligned with Vision 2030’s ambitions.

Signed at KAEC by Abdulaziz Alnowaiser, CEO of EEC, and Robert Hofmann, CEO of Al Tahaluf, the agreement covers the acquisition of 340 residential lots, ranging from 600 m² to 1,000 m², with built up areas spanning 400 m² to 600 m². These exclusive communities are inspired by a tropical modernism design approach, introducing a signature architectural villa style to the Kingdom. The four–to–five–bedroom villas will offer resort–styled living with expansive glass façades, soaring ceilings, shaded terraces, lush tropical landscaping, and premium finishing. Open concept layouts will connect indoor and outdoor spaces, with gourmet kitchens and private two–car garages, including space for a golf buggy, to support sustainable mobility.

The project is tailored for buyers looking to enjoy elevated living along the Red Sea coast, with interest expected to only rise following a recent decision by the Saudi Cabinet to allow foreign property ownership in designated zones starting 2026.

Commenting on the signing, Abdulaziz Alnowaiser, CEO of EEC, said: “This agreement highlights KAEC’s continued evolution into a vibrant and future–ready city, offering high–quality residential, commercial, and leisure opportunities. We are delighted to partner with Al Tahaluf, whose presence signals strong investor interest in KAEC’s long–term potential as a destination of choice for home buyers in the Kingdom.”

“We at Al Tahaluf are incredibly proud to be part of KAEC’s next chapter as a premier luxury lifestyle destination in the Kingdom,” said Robert Hofmann, CEO of Al Tahaluf. “Set along the breathtaking Red Sea coastline, our new communities at KAEC will offer an unparalleled setting with opportunities for world class championship golf, relaxation, wellness, and a full spectrum of watersports and waterside leisure. With seamless access to the Holy Cities of Mecca and Medina, as well as King Abdulaziz International Airport in Jeddah via the Haramain High Speed Railway, KAEC provides future residents with unmatched connectivity. Combined with pristine beaches, and visionary urban design, it is poised to become a destination of choice for both Saudi and international homebuyers and investors.” Hofmann added that K. Hovnanian, a leading American homebuilder and managing partner of Al Tahaluf, will bring its expertise in lifestyle communities and its high–quality standards to the project.

Al Tahaluf has set a target of late 2025 to launch sales of the villas. A formal design unveiling is also planned for Cityscape Global later this year.

This strategic collaboration advances EEC’s ambition to attract foreign direct investment and enable greater private sector participation. With its blend of world–class infrastructure, lifestyle–driven planning, and proximity to Jeddah and the western coast, KAEC continues to strengthen its position as a coastal premier lifestyle destination.

The deal also adds momentum to KAEC’s expanding development pipeline and aligns with national efforts to diversify the economy and expand high–impact sectors under Vision 2030.

Robert Hofmann, Chief Executive Officer
Al Tahaluf Real Estate Company
Saudi: +966 543 853 901
US: 732 904 4876

Tyler Lewis, Director of Investment
Al Tahaluf Real Estate Company
Saudi: +966 55 287 4982
US: 713–248–2624


GLOBENEWSWIRE (Distribution ID 9502595)

DebitMyData Closes Oversubscribed Seed Round- Launches $1B Human Energy Grid Global Expansion

DebitMyData™ Logo

FORT LAUDERDALE, Fla., July 30, 2025 (GLOBE NEWSWIRE) — DebitMyData™, Inc.—the powerhouse has closed a seed round at more than twice its original target. This surge of investor confidence paves the way for a bold, billion–dollar global rollout of DebitMyData™’s Human Energy Grid, setting a new standard for individual data ownership, ethical monetization, and human–centric AI innovation.

Preparing to launch a U.S and global expansion round, DebitMyData™ is already attracting top–tier venture capitalists—some of whom previously backed OpenAI alumni Ilya Sutskever and Mira Murati. Their attention is now focused on founder Preska Thomas and her breakthrough vision for a decentralized, human–led future in Adtech, AI, cybersecurity, and digital sovereignty.

“We’re advancing AI frameworks including Fuzzy Logic, ML, NLP, and robotic networks—but the Human Energy Grid ensures we embed ethics, skills, and human vision at the algorithmic core,” said Preska Thomas, Founder & CEO.

Agentic Logos, Nodes, and Verified Digital Identity

Integral to DebitMyData™ 's technology are Agentic Logos—cryptographically validated identity tools that combat fraud, impersonation, and deepfakes.

Core LLM Features:

  • Verified Ownership: Every identity is cryptographically bound to an authentic user or brand.
  • Real–Time Security: Proprietary consensus mechanisms eliminate spoofing and fakes.
  • Plug–and–Play APIs: Enterprises and large language models (LLMs) can easily verify and interface with Agentic Nodes.

By embedding identity–driven trust into content and advertising, DebitMyData™ transforms audience engagement. Brands and individuals alike benefit from frictionless, permission–based experiences that foster credibility and prevent misuse.

The Human Energy Grid: An Ethics–Powered Digital Ecosystem

DebitMyData™’s signature innovation—the Human Energy Grid—places people at the center of the digital economy.

Key Components:

  • Digital Ownership: Users control and protect their digital footprints via DID–LLM (Digital Identity LLM).
  • Agentic Avatars: AI agents trained and owned by users, supporting monetization through sponsorships, licensing, and personal branding.
  • Ethical AI Training: Decentralized Agentic Avatars contribute to safe, human–aligned AI development.
  • NFT–Backed Security: Blockchain–protected digital creations ensure transparent royalties and rights.
  • Quantum–Resistant Privacy: Federated learning and next–generation encryption secure all interactions.

This ecosystem empowers individuals to earn from their data and digital identity, marking a shift from extractive models toward equitable participation in the digital economy.

Global Expansion and Ecosystem Integration

Building on its momentum, DebitMyData™ is launching a global initiative to:

  • Open subsidiaries in the EU, Asia, and the Middle East
  • Advance Agentic Avatar technology for LLMs, APIs, and user–controlled AI
  • Partner with NFT platforms and creator–centric brands like AnimeGamer, MemeShorts (“The TikTok of America”), and Monetize YourSelfie

The roadmap includes further integration across decentralized marketplaces for data, content, and avatar–based economies.

Institutional & Government Alignment

DebitMyData™ is engaged in advanced discussions with regulatory bodies, family offices, and public sector partners worldwide, reinforcing its commitment to compliance, transparency, and leadership in large–scale data solutions.

Image by DebitMyData™

About DebitMyData™, Inc.

DebitMyData™, Inc. enables users to reclaim, verify, and monetize their digital identities through Agentic Logos and Agentic Avatars. Its scalable platform ensures GDPR compliance and AI alignment via the Human Energy Grid and DID–LLM, meeting evolving demands in ethical AI, cybersecurity, and digital equity.

“This is our moment—not just to advance AI but to protect what makes us human. The Human Energy Grid ensures humanity stays present, empowered, and valued in the algorithms that shape the future,” said Preska Thomas, Founder & CEO.

For more information, visit:

Media Contact:
Henry Cision
(754) 315–2420
[email protected]
https://debitmydata.com/

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/2eea9b1e–727f–4c0a–8e52–646b9df41730

https://www.globenewswire.com/NewsRoom/AttachmentNg/f60b8de6–b43e–47ef–ac82–34baa1408038

A video accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/c791ff1b–73dd–4a37–b042–60f8e5c2a1c2


GLOBENEWSWIRE (Distribution ID 9502083)

As Heatwaves and Floods Surge, U.S. Agriculture Faces a Growing Crisis

Heatwaves and floods are damaging essential crops like corn, wheat, rice, and tomatoes—threatening food and nutrition security. Credit: Shutterstock - Extreme weather and agriculture are increasingly at odds, as heatwaves and floods devastate U.S. crops, threaten food security, and demand urgent action

Heatwaves and floods are damaging essential crops like corn, wheat, rice, and tomatoes—threatening food and nutrition security. Credit: Shutterstock

By Esther Ngumbi
URBANA, Illinois, US, Jul 30 2025 – Recent weeks have seen an increase in extreme weather events. From heat waves occurring across the Midwest states to flash flooding in Texas, Maryland, and New York.

Although these weather events have had significant and measurable impacts on humans, rarely making headlines are the detrimental impacts these events have on agriculture, and that lack of coverage needs to change.

Most concerning is the noticeable gap in dialogue and focused attention by researchers, policy makers and other key stakeholders in agricultural crop production and food systems, a gap that urgently needs to change as well.

It’s time for researchers, policy makers, governments, media, and stakeholders across agriculture and food systems to engage more urgently in how these events affect not just humans, but also how they detrimentally impact agricultural crops and the microbial communities that support soils and agricultural crops health

Heat and flooding impact the crops such as corn, wheat, rice, and vegetable crops including tomato that we depend on to meet food and nutritional security needs.

These impacts can range from changes in growth patterns, acres of crops decimated to tons of vegetables unsellable due to potential contamination by flooding waters. All these losses also have a dollar value associated with them.

For example, the University of Arkansas System Division of Agriculture estimated crop-related flooding damage in Arkansas in 2025, to be $78.9 million

Indeed, recent research coming from research institutions and universities across United States universities has demonstrated that these events detrimentally affect agricultural crop growth and production, resulting in reduced yields and agricultural crop revenue, while driving up prices and crop insurance payments.

Heatwaves and flooding also impact plant physiology and metabolism, disrupting the life-sustaining processes of plants, including photosynthesis, respiration, the antioxidant defense system, and reactive oxygen species scavenging. These changes hinder plant growth and development, leading to reduced crop productivity and yield losses.

Ultimately, farmers lose their crops and the revenue they get from farming, and these losses are passed on to consumers through increased prices. For example, according to The American Farm Bureau Federations, in 2024, farmers lost $20.3 billion to weather disasters including flooding and heat waves.

Extreme weather also affects the multitude of belowground microbes that underpin the health of soil, its functions, health, and quality, as well as the soil microbiomes that govern soil and plant health and key biogeochemical processes, including nutrient and water cycling. Both beneficial and pathogenic microbes are impacted by flooding.  

Flooding, for example, has been reported to impact soil microbial communities negatively, depleting beneficial soil microbes, and affecting other beneficial soil-dwelling organisms, such as earthworms.

And because belowground processes are tightly linked and interconnected with aboveground processes, changes in the health and productivity of crops can be impacted by changes in belowground dwelling organisms.

Importantly, researchers are rising to the challenge of finding solutions to mitigate the trail of damage that these extreme events have on agricultural crops and production systems both during and after these events have happened.

Take the case of flooding; emerging research reveals that applying nitrogen-based fertilizers immediately after a flooding event can help rescue plants from the detrimental impacts of flooding.

Disturbingly, however, although nitrogen fertilizer can help mitigate flooding impacts, its use is not sustainable due to its negative impacts on ecosystems, including polluting groundwater and streams, while contributing to the greenhouse effect. Therefore, researchers must push the boundaries beyond nitrogen.

Fortunately, the agricultural market is filled with sustainable bioproducts, including biostimulants and microbial inoculants. These products, that contain live microorganisms such as mycorrhizal fungi, nitrogen-fixing bacteria or other groups of beneficial microbes, have potential in mitigating the detrimental impacts that extreme weather events have on crops, and their investigation should be considered.

Excitingly, this is beginning to happen. For example, a recent study revealed that foliar spraying tomato plants with microbes improved their tolerance against acute heat wave stress. In addition, review papers are being published that detail what we currently know, while outlining future research questions to explore further.

Moving into the future, this line of research needs to be funded so that the excitement in using these products as well as the challenges that come along with using biostimulants including a lack of regulation and unified terminology and the growing concerns that introduced microorganisms could mutate as they adapt to environments can be addressed. The use of biostumulants is expected to keep growing, with global market estimated to reach USD 7.84 billion by 2030.

Notably, there is a need to think of long-term solutions. Thankfully, regenerative agriculture approaches, including the use of cover crops, can be utilized. Further, recent research is reaffirming this and has revealed that cover crops can mitigate the effects of flooding, thus enhancing resilience to extreme weather events.

Cover crops are plants that are primarily grown to provide several benefits including improving water infiltration, soil health and structure, and controlling erosion. These crops can be important long-term tools to mitigate extreme weather events including mitigating flooding risks by absorbing excess soil water while improving soil physical properties. 

Although the use of cover crops continues to gain traction in the United States, rising by 17% between 2017 and 2022, according to recent satellite-based research from that analyzed 100, 000 fields, their adoption and use can pose some challenges and potential drawbacks that continue to warrant more research and consideration.

Future projections indicate that many extreme weather events including flooding will continue to increase in both intensity and frequency.

It’s time for researchers, policy makers, governments, media, and stakeholders across agriculture and food systems to engage more urgently in how these events affect not just humans, but also how they detrimentally impact agricultural crops and the microbial communities that support soils and agricultural crops health.

By acknowledging and documenting these impacts through research, we can begin to develop sustainable, science driven solutions, both short and long term.  The time is now.

Esther Ngumbi, PhD is Assistant Professor, Department of Entomology, African American Studies Department, University of Illinois at Urbana-Champaign

ICJ Ruling Is a Pivotal Moment for Climate and Health Justice, Experts Say

Cyclone damage in Vanuatu. Credit: UNICEF/ReliefWeb

By Tanka Dhakal
THE HAGUE, Jul 30 2025 – Legal minds in international law are trying to interpret the scope and impact of the landmark advisory opinion on climate change by the International Court of Justice (ICJ), where it said that states have a duty to prevent significant harm to the environment.

The court ruling says that the states have a responsibility to cooperate internationally to prevent the impact of climate change. It didn’t directly link climate change and the health crisis but recognized the health aspect through the “right to a clean, healthy and sustainable environment.” Organizations advocating for the health-related actions in the climate change discussion are saying the court opinion affirmed “climate crisis as health crisis.”

Yamide Dagnet,

  • All countries have an obligation to address climate change under international and customary laws, beyond their commitments under the Paris Agreement.
  •  It provides legal leverage to seek reparations from major emitters, including from the fossil fuel industry.
  • Small islands will keep their statehood if their land disappears due to sea level rise—as illustrated by the Rising Nation Initiative, Global Centre for Climate Mobility—thus boosting their efforts to preserve their sovereignty, rights, and cultural heritage with dignity.

Dr Jeni Miller, Executive Director at the Global Climate and Health Alliance said the court has delivered a historic affirmation that the climate crisis is a health crisis-and failure to act is a failure to protect life

“This ruling confirms that governments and corporations have a legal duty to prevent further harm, uphold the right to health, and safeguard future generations,” she said in a statement. “From deadly heat and toxic air to disease and displacement, the Court’s message is clear-human health is not collateral damage.”

The ICJ issued its ruling on July 23 in response to a United Nations (UN) General Assembly resolution led by Vanuatu, the small island nation in the Pacific, which knocked on the ICJ’s door asking for an advisory opinion on the obligation of the states to address climate change and its legal consequences.

Following a long hearing last December, the ICJ delivered its first opinion on climate change. “The case was unlike any that have previously come before the court,” President of the International Court of Justice Judge Yuji Iwasawa said while reading the court’s unanimous advisory opinion. “This case was not simply a legal problem but concerned an existential problem of planetary proportions that imperils all forms of life and the very health of our planet.”

Pivotal moment for climate and health justice

While addressing planetary health, the court laid out the case for the impact of human-induced climate change and its impact on growing health concerns. In its ruling the court took note of participants discussing the existence of a right to a clean, healthy and sustainable environment.

During the hearing of the case in December Dr Tedros Adhanom Ghebreyesus testified to the court and said climate change is fundamentally a health crisis. “The climate crisis is among the most significant health challenges facing humanity today,” he said during his testimony to the court.

Experts believe that health workers and advocates now have powerful legal backing to demand bold, science-based climate action rooted in justice. They are still reviewing the court’s opinion to make a more nuanced analysis and said it marks a pivotal moment for climate and health justice. Shweta Narayan, Campaign lead at the Global Climate and Health Alliance, said the ruling affirms the urgency of comprehensive, rights-based action that addresses both immediate health harms and the root causes of the crisis.

“This represents a major step forward in reframing the climate crisis as fundamentally a health crisis-and in mobilizing the legal, scientific, and political tools needed to respond,” she adds.

“This ruling strengthens the moral mandate to place health at the center of climate negotiations, including in adaptation, loss and damage, and climate finance frameworks.”

The court used the human rights approach to address the health aspect of climate change in its ruling. In a rapid legal analysis, Vanuatu, who led the campaign for the opinion, also welcomed the ruling.

“The opinion integrates international human rights law, identifying the rights to life, health, an adequate standard of living, and the right to a clean, healthy and sustainable environment as directly threatened by climate change,” the Vanuatu Climate Justice Program said in a statement. “It affirms that environmental protection is a precondition for their enjoyment.”

Dagnet added that it demonstrated the power of activism.

“The students of Vanuatu dared to dream big and challenge the status quo, and it paid off with what could end up being one of the most important milestones in the global climate fight. I am thrilled at the landmark International Court of Justice (ICJ) decision to validate some of the most ambitious climate priorities championed by vulnerable states over the last 50 years.”

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById({js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

 

Marital Rape: Confronting Religious Misinterpretations, Social Stigma, Despite Legal Clarity

From beautiful bride, to victim of marital rape, this is the story of Shanti, a 19-year-old whose husband has been charged under the Domestic Violence (Prevention and Protection) Act of 2013.

From beautiful bride, to victim of marital rape, this is the story of Shanti, a 19-year-old whose husband has been charged under the Domestic Violence (Prevention and Protection) Act of 2013.

By Zofeen Ebrahim
KARACHI, Pakistan, Jul 30 2025 – “The last thing she asked for was a sip of water,” recalled Najma Maheshwari, referring to 19-year-old Shanti, a newlywed who died last week after brutal sexual violence allegedly inflicted by her husband, who is now in custody.

“Then she closed her eyes and never opened them again,” she said quietly, her voice steeped in sadness.

Najma, a social activist from Shanti’s neighborhood, accompanied her brother Sayon to the government-run Shaheed Benazir Bhutto Trauma Centre. “Her insides were torn, she was bleeding profusely from her anus and writhing in pain. Hospital visitors urged us to move the gurney outside, complaining the stench was unbearable.

“While cleaning her, medics removed worms from her gut—her injuries were that severe. I’ve seen much in my work, but never such horror or pain,” Najma told IPS by phone from her home in Lyari, an informal settlement in Karachi.

Najma Maheshwari, the social activist who was with Shanti when she died.

Najma Maheshwari, the social activist who was with Shanti when she died.

After two weeks at the hospital and a day trip to attend Shanti’s funeral in her village, 38-year-old Najma—mother of four—was deeply shaken. “I can’t eat, and the indescribable stench still haunts me,” she said.

According to the complaint lodged by Sayon with the police, Shanti’s husband, Ashok Mohan, had “inserted a metal pipe” followed by his “hand and arm” in her anus two days after her marriage. Not content, he bit her on her breasts and neck and threatened to kill her if she disclosed the act to anyone.

“They were engaged for two years before we married her off; she was very happy during the celebrations,” recalled Sonya, Shanti’s sister-in-law, adding the groom, 25, lived just a few lanes away and seemed like a good match.

The sexual violence, just three days after her marriage, led Shanti to bleed heavily from the anus. When the bleeding wouldn’t stop, her in-laws took her to two health facilities, but when the doctors gave up, they brought her home.

“We went to see her… she lay motionless, and her mother-in-law claimed it was just diarrhea and her period, so we left, not realizing how serious it was,” said Sonya.

Two weeks later, as Shanti’s condition worsened, her in-laws called her brother. Seeing her state, he rushed her to the hospital—but it was too late.

“There was clear evidence of anal trauma caused by sexual violence,” confirmed Dr. Summaiya Sayed, Karachi’s chief police surgeon, saying Shanti was brought in “comatose” and placed on a ventilator. Her injuries worsened as she continued passing stool, leading to her death three weeks later.

“This is a clear-cut case of marital rape,” said Syeda Bushra, a lawyer at Karachi-based Legal Aid Society, which provides free legal aid. She has handled sexual violence cases for nearly a decade.

While no specific law currently defines marital rape, the Domestic Violence (Prevention and Protection) Act of 2013 holds husbands accountable as violators.

“Though the law may not explicitly mention marital rape, its broadened definition under Section 376 of the Pakistan Penal Code allows prosecution of husbands,” explained Bushra.

This marks a significant shift from Section 375 of the PPC, which previously exempted marital sex—an exemption removed in 2006 by the Protection of Women (Criminal Laws Amendment) Act.

Bushra described marital rape as “undeniably a form of domestic abuse” but noted it remains rarely reported. Many women choose divorce instead, as marital rape is still taboo and often not even recognized as such.

Government surveys reveal grim realities: the Pakistan Demographic and Health Survey (PDHS) reported that 47 percent of respondents in 2012–2013 considered wife-beating justifiable—a figure that only slightly declined to 43 percent by 2017–2018. The World Economic Forum’s 2023 data paints an even darker picture, showing that 85 percent of married women in Pakistan experience physical or sexual violence—far higher than Bangladesh’s 53 percent and India’s 29 percent.

Islamabad-based gender and governance expert Fauzia Yazdani highlights how religious texts and traditions are often deliberately misinterpreted to justify abuse. Supporting Yazdani’s view, lawyer Bushra notes that women brave enough to seek justice frequently face defense attorneys citing selective Quranic verses to defend their husbands. “It’s not just disturbing—it’s deeply problematic,” Bushra said.

While activists challenge these harmful narratives, legal experts push for accountability within the justice system.
“The cruelty of the act that led to Shanti’s death means her husband may face charges of both rape and murder, setting a vital precedent for criminalizing marital rape,” said Bahzad Akbar, a lawyer at the Legal Aid Society who has specialized in gender-based violence cases for four years.

In 2022, Akbar secured Sindh’s first-ever marital rape conviction, where the husband was sentenced to three years’ imprisonment and fined Rs 30,000 (USD 106) for sodomy. But it took two years for the verdict.

Najma (centre), Sonya (on Najma's left in yellow), her brother on Najma's right (centre) sitting on the pavement, outside the trauma centre where Shanti lay fighting for her life. Credit: Seema Maheshwari

Najma (center), Sonya (wearing yellow on Najma’s left), and their brother (on Najma’s right) were sitting on the pavement outside the trauma center where Shanti was fighting for her life. Credit: Seema Maheshwari

Today, with the 2021 Anti-Rape Act having established special courts, Akbar is hopeful for a swift trial and justice in Shanti’s case.

“Shanti’s case will be a test for society,” he said, “Offering hope to women enduring sexual abuse in marriage that justice is possible.”

Tragically, Shanti’s case did not spark widespread outrage.

“That’s because she was a woman, and in this society, women are seen as disposable,” explained Yazdani.

According to her, gender-based violence is rarely recognized as a crime in Pakistan’s collective mindset, which is why it remains inadequately addressed within institutions.

“There’s still no official definition for misogyny and patriarchy; there are no local terms capture these concepts,” she said, holding the government, the judiciary, the police, the country’s opinion makers, and even independent oversight bodies responsible for failing the Pakistani women “over and over again.”

This disconnect between societal attitudes and institutional responses, she argued, creates a void that even robust laws struggle to bridge.

Legal experts acknowledge that while Pakistan has strong laws protecting women, enforcement remains weak.

“When laws are made in a social vacuum, what do you expect; they will remain ineffective,” observed Yazdani.

That disconnect between law and lived reality is starkly visible in the experiences shared by healthcare professionals.

“I meet smart, accomplished women who still believe they have no right to refuse their husbands. Many see sex without consent as their marital duty,” said Dr. Azra Ahsan, a senior gynecologist and obstetrician based in Karachi.

After years of hearing young, married women quietly confide their pain—often long after the damage was done—Dr. Ahsan became convinced that sexual and reproductive health (SRH) education is crucial to raising awareness about reproductive health, including marital rape.

To fill this gap, she and a group of like-minded doctors at the Association for Mothers and Newborns (AMAN)*—the implementation arm of Pakistan’s National Committee for Maternal and Neonatal Health—developed Bakhabar Noujawan (Informed Youth), an online SRH program endorsed by the Ministry of National Health Services, Regulations and Coordination, launched in 2023.

“We’re trying to introduce it in colleges, but convincing faculty is an uphill battle—they first need to grasp the course’s importance,” she said.

Covering over two dozen culturally sensitive topics—from premarital counselling, child and cousin marriage, domestic violence, STIs, to teenage pregnancy—the programme doesn’t shy away from tough conversations. “We’re now developing a module on marital rape,” says Ahsan, head of AMAN. “The first draft is nearly complete.”

Alongside SRH education, Sayed emphasized the need for mental health and emotional wellness programs.

“Too many young people carry the trauma of childhood sexual abuse,” she said. “As they grow, that buried pain can manifest in troubling ways—some develop sadistic or masochistic behaviors, especially when exposed to unchecked pornography. It doesn’t heal them; it deepens the harm.”

Lawyer Akbar, who has handled nearly two dozen child sexual abuse cases over the past four years, said 70% involved incest. At Karachi’s three medicolegal centers, Sayed reports 4–8 sexual violence cases daily, yet only three alleged marital rape cases were recorded in 2024—underscoring severe underreporting.

Experts say this silence stems from deeply entrenched norms conditioning women to endure abuse rather than speak out.

“Even today, parents tell their daughters at marriage, ‘Your husband’s home is your final home—you should only leave it in death’,” said Yazdani, adding that Pakistani society remains bound by social mores that consistently deny women their rights. “She is compartmentalized and viewed only through the lens of relationships, her duty simply to obey the men around her—father, brother, husband, even her son.”

* The writer serves on the executive committee of this nonprofit in a voluntary capacity but had no part in the development of the SRH course.

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById({js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Dr. Falk Pharma und Allianthera (Suzhou) Biopharmaceuticals gehen strategische Partnerschaft für die Entwicklung eines neuartigen AhR-Agonisten ein

Freiburg (Deutschland), Suzhou (China) und Boston (USA), 30. Juli 2025: 

Dr. Falk Pharma GmbH und Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. geben strategische Partnerschaft für die Entwicklung eines neuartigen AhR–Agonisten zur Behandlung mittelschwerer bis schwerer Colitis ulcerosa bekannt.

Dr. Falk Pharma GmbH, ein forschungsbasiertes Pharmaunternehmen und Spezialist für Verdauungs– und Stoffwechselmedizin, und Allianthera (Suzhou) Biopharmaceuticals Co., Ltd., sowie sein verbundenes Unternehmen Allianthera Boston, Inc., ein Biotechnologieunternehmen mit Fokus auf klinischer Forschung und Entwicklung neuartiger Arzneimittel im Bereich Immunologie und entzündlicher Erkrankungen (Allianthera), geben die Unterzeichnung eines Vertrages über die gemeinsame Entwicklung, mögliche Lizenzierung, Herstellung und Vermarktung des neuartigen, niedermolekularen Aryl–Hydrocarbon–Rezeptor–(AhR–)Agonisten ATB102 bekannt, der gegenwärtig eine klinische Studie der Phase I in den USA durchläuft.

Im Rahmen des neu unterzeichneten Vertrags werden Dr. Falk Pharma und Allianthera gemeinsam an der Entwicklung von ATB102 zur Behandlung entzündlicher Darmerkrankungen mit anfänglichem Fokus auf refraktärer, mittelschwerer bis schwerer Colitis ulcerosa (CU) arbeiten. Dr. Falk Pharma erhält die Exklusivrechte für die Lizenzierung, Herstellung und Vermarktung von ATB102 auf der ganzen Welt, mit Ausnahme von Festlandchina, Hongkong, Macau und Taiwan. Allianthera erhält eine Einmalzahlung bei Vertragsunterzeichnung, Zahlungen bei der Erreichung wesentlicher Entwicklungsmeilensteine sowie eine Lizenzgebühr und anschließend, während der Vermarktung, bestimmte Meilensteinzahlungen und gestaffelte Lizenzgebühren.

Bei dem von Allianthera entwickelten Wirkstoff ATB102 handelt es sich um einen auf den Darm beschränkten AhR–Agonisten, der einen neuen therapeutischen Ansatz bei entzündlichen Darmerkrankungen darstellt. Er richtet sich speziell gegen Entzündungen und Schleimhautschäden im Gastrointestinaltrakt, mit besonderem Schwerpunkt auf der Behandlung refraktärer, mittelschwerer bis schwerer CU. Aus präklinischen Daten geht hervor, dass ATB102 die Immunhomöostase unterstützt, die Integrität der Schleimhautbarriere wiederherstellt und zudem antifibrotischen und antioxidativen Nutzen mit sich bringt, was diesen Wirkstoff zu einer potenziellen neuen Therapieoption für Patient*innen macht, die nicht auf bestehende Therapien ansprechen oder ein Rezidiv erlitten haben.

Dr. Falk Pharma wird, in Zusammenarbeit mit seiner 100%igen Tochtergesellschaft Losan Pharma GmbH, einem international führenden Auftragsentwicklungs– und –herstellungspartner (CDMO) und Galenikexperten, eine innovative Formulierung von ATB102 mit gezielter Freisetzung im Darm entwickeln, um die derzeitige Formulierung, die auf einer sofortigen Freisetzung beruht, zu ergänzen.

„Der Aryl–Hydrocarbon–Rezeptor stellt einen wahrhaft neuartigen Wirkmechanismus dar, um auf den erheblichen unerfüllten medizinischen Bedarf bei entzündlichen Darmerkrankungen, und insbesondere bei Colitis ulcerosa, einzugehen. Das ATB–Team hat einen unserer Ansicht nach erstklassigen AhR–Agonisten entdeckt, der hinsichtlich der Sicherheit, Anreicherung im Darm und therapeutischen Wirkung optimiert ist. Wir freuen uns sehr auf die Zusammenarbeit mit Dr. Falk Pharma, einem Unternehmen mit tiefgehender Fachkompetenz in Formulierung und klinischer Entwicklung. Wir sind davon überzeugt, dass wir dieses Programm durch die Kombination unserer komplementären Stärken beschleunigen können und den Patient*innen damit schneller als je zuvor eine dringend benötigte Therapie von hoher Qualität zur Verfügung stellen können“, erklärt Yuanhua Ding, CEO von Allianthera.

Dr. Kai Pinkernell, Geschäftsführer des Geschäftsbereichs Science & Innovation bei Dr. Falk Pharma, fügt hinzu: „Wir sind begeistert, unsere F&E–Pipeline um ATB102 ergänzen zu können, und freuen uns darauf, das Potenzial dieses neuartigen Moleküls in zukünftigen klinischen Studien gemeinsam mit Allianthera zu erforschen. Die Partnerschaft mit Allianthera steht für die Kraft wissenschaftlicher Exzellenz, gegenseitiges Vertrauen und eine gemeinsame Vision, Menschen mit entzündlichen Darmerkrankungen zu besserer Lebensqualität zu verhelfen. Diese Zusammenarbeit spiegelt nicht nur unsere wachsende weltweite Entwicklung und unser Engagement für Innovation in Bereichen mit hohem unerfüllten medizinischen Bedarf wider, sondern wird auch das Wirkstoffportfolio von Dr. Falk Pharma für die Behandlung von Erkrankungen des Verdauungstrakts erweitern.“

Über Colitis ulcerosa
Colitis ulcerosa gehört zur Gruppe der chronisch entzündlichen Darmerkrankungen (CED). Weitere Erkrankungen aus dieser Gruppe sind Morbus Crohn sowie die mikroskopischen Kolitiden lymphozytäre und kollagene Kolitis.

Colitis ulcerosa ist auf den Dickdarm beschränkt und beginnt typischerweise im Rektum, wobei sich die Entzündung kontinuierlich über den restlichen Teil des Dickdarms ausbreiten kann. Die genaue Ursache der Colitis ulcerosa ist noch unklar; jedoch werden derzeit eine Fehlfunktion des Immunsystems, genetische Faktoren, ein Ungleichgewicht des Darmmikrobioms sowie eine Dysregulation der Integrität der intestinalen Schleimhaut oder Umweltfaktoren als mögliche Auslöser untersucht.

Weitere Informationen finden Sie auf der Seite der Dr. Falk Pharma: https://de.drfalkpharma.com/de/indikationen/colitis–ulcerosa/

Über Allianthera
Allianthera wurde im November 2020 mit einem Forschungs– und Entwicklungszentrum in Suzhou, China, und einer Tochtergesellschaft in Boston, USA, gegründet. Allianthera hat es sich zum Ziel gesetzt, weltweit führend in therapeutischer Innovation zu werden, indem es sein umfassendes pathophysiologisches Wissen und seine führende Expertise in der Forschung und Entwicklung neuartiger Wirkstoffe mit Technologien von Kooperationspartnern kombiniert und gleichzeitig einzigartige Stärken in verschiedenen Regionen, in Ost oder West, nutzt. Das Unternehmen baut durch interne F&E–Programme und externe Partnerschaften ein starkes Wirkstoffportfolio auf, wobei der anfängliche Fokus auf der Behandlung immunologischer und entzündlicher Krankheiten mit hohem ungedecktem medizinischem Bedarf liegt.

Weitere Informationen zu Allianthera finden Sie auf LinkedIn: https://www.linkedin.com/company/allianthera–suzhou–biopharmaceutical–co–ltd

Partnerschaften mit Dr. Falk Pharma
Dr. Falk Pharma kooperiert mit zuverlässigen Partnern, um innovative Behandlungskonzepte mit Potenzial zu entwickeln und umzusetzen. Diese können aus jeglichen pharma–kologischen Konzepten hervorgehen: von „Small Molecules“ bis hin zu Biologika oder neuartigen Drug–Delivery–Technologien. In seinen Partnerschaftsprojekten betrachtet das Familienunternehmen verschiedenste Entwicklungsschritte in allen Phasen der prä–klinischen/klinischen Entwicklung und Vermarktung, die ihren Ursprung in der akademischen Forschung, im klinischen Einsatz, in Start–ups oder auch in etablierten Firmen haben können.

Dr. Falk Pharma ist ein Branchenführer für innovative Arzneimittelformulierungen, die Wirkstoffe zu bestimmten funktionalen Abschnitten des Magen–Darm–Traktes transportieren. Viele ihrer Produkte gelten als Behandlungsstandard. Das Unternehmen baut auf die langjährige enge Zusammenarbeit mit renommierten klinischen Zentren und wichtigen akademischen und klinischen Meinungsbildnern in den Bereichen Gastroenterologie, Hepatologie und Stoffwechselerkrankungen.

Mehr Informationen und Kontaktdaten gibt es unter https://de.drfalkpharma.com/de/partnering/

Über die Dr. Falk Pharma GmbH
Die Dr. Falk Pharma GmbH mit Sitz in Freiburg entwickelt und vertreibt seit über 60 Jahren innovative Arzneimittel für verschiedene Erkrankungen der Leber, der Gallenwege, des Darms und der Speiseröhre. Als internationaler Spezialist für Verdauungs– und Stoffwechselmedizin bringt das Unternehmen Ärztinnen und Ärzte, Wissenschaftler*innen und Patient*innen zusammen, um neue und wirkungsvolle Ansätze der Versorgung der Betroffenen zu entwickeln. Im Fokus der Forschungsinvestitionen und Studien steht das Ziel, die klinische Praxis und das Leben der Patient*innen nachhaltig zu verbessern. Das stetig wachsende Familienunternehmen mit globaler Vernetzung und 10 Tochtergesellschaften in Europa und Australien forscht und entwickelt in Freiburg. Hergestellt werden die pharmazeutischen Produkte in Europa, größtenteils in Deutschland, Frankreich, Italien und der Schweiz. Das mit der Region Breisgau tief verbundene Unternehmen beschäftigt rund 1400 Mitarbeiter*innen, davon 340 in Freiburg.

Weitere Informationen über die Dr. Falk Pharma finden Sie unter: www.drfalkpharma.de


GLOBENEWSWIRE (Distribution ID 1001120434)

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: 

Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis 

Dr. Falk Pharma GmbH, a research–based pharmaceutical company specializing in digestive and metabolic medicine, Allianthera (Suzhou) Biopharmaceuticals Co., Ltd., and its affiliate Allianthera Boston, Inc., a clinical stage biotechnology company focusing on novel drug research and development in immunology and inflammatory diseases, (Allianthera), are pleased to announce the signing of an agreement on the co–development, license option, manufacturing, and commercialization of the novel small molecule ATB102, an aryl hydrocarbon receptor (AhR) agonist currently undergoing a phase 1 clinical trial in the United States.

Under the terms of the newly signed agreement, Dr. Falk Pharma and Allianthera will collaborate to develop ATB102 for inflammatory bowel disease (IBD), with an initial focus on refractory moderate–to–severe ulcerative colitis (UC). Dr. Falk Pharma will enjoy the exclusive rights to license, manufacture, and commercialize ATB102 worldwide, excluding Mainland China, Hong Kong, Macau and Taiwan. As part of the agreement, Allianthera will receive a signing fee, significant development milestone payments as well as a licensing fee, followed by sales milestone payments and tiered royalties.

ATB102, developed by Allianthera, is a gut–enriched AhR agonist which represents a new therapeutic approach for IBD. It is designed to specifically target inflammation and mucosal damage within the gastrointestinal tract, with a particular emphasis on treating refractory moderate–to–severe UC. In pre–clinical research, ATB102 supports immune homeostasis, restores mucosal barrier integrity, and confers anti–fibrotic and anti–oxidative benefits, making it a potential new option for patients unresponsive to or relapsed from existing therapies.

Dr. Falk Pharma, in cooperation with its fully–owned subsidiary Losan Pharma GmbH, a leading contract development and manufacturing organisation (CDMO) partner and formulation expert, will develop an innovative colonic–release formulation of ATB102 to complement the current immediate release formulation.

“The aryl hydrocarbon receptor represents a truly novel mechanism of action to address the significant unmet needs in inflammatory bowel disease – especially in ulcerative colitis. The ATB team has discovered what we believe to be the best–in–class AhR agonist optimized for safety, gut enrichment, and therapeutic impact. We are delighted to join forces with Dr. Falk Pharma, who has deep expertise in formulation and clinical development. By combining our complementary strengths, we are confident that we will accelerate this program and deliver a much–needed, high–quality therapy to patients faster than ever before,” said Yuanhua Ding, CEO of Allianthera.

Kai Pinkernell, M.D., Managing Director, Science & Innovation at Dr. Falk Pharma, added, “We are excited about the addition of ATB102 to our R&D pipeline and to further exploring the potential of this novel molecule in future clinical trials together with Allianthera. The partnership with Allianthera reflects the strength of scientific excellence, mutual trust and a shared vision to better the lives of patients suffering from IBD. This collaboration not only reflects our growing global development and commitment to innovation in areas of high unmet medical need, it will also enhance Dr. Falk Pharma´s portfolio to treat digestive diseases and conditions.”


About Ulcerative Colitis
Ulcerative colitis is one of the disorders known as inflammatory bowel disease (IBD). Other disorders within this group of conditions include Crohn’s disease and two forms of microscopic colitis, called lymphocytic and collagenous colitis.

Ulcerative colitis is confined to the colon and typically begins in the rectum, spreading continuously throughout the rest of the large intestine. The exact cause of ulcerative colitis is still unclear; however immune system dysfunction, genetic factors, gut microbiome imbalance and dysregulation of the intestinal mucosal integrity as well as environmental factors are currently being investigated as potential contributors.

For more information, visit Dr. Falk Pharma’s website: https://drfalkpharma.com/en/indications/ulcerative–colitis/


About Allianthera 
Allianthera was established in November 2020 with a research and development (R&D) center in Suzhou, China, and a subsidiary in Boston, USA. Allianthera strives to become a global leader in therapeutic innovation by combining their deep disease biology knowledge and industry–leading R&D expertise with partners’ technologies while leveraging unique strengths in different geographies, East or West. The company is building a strong portfolio through internal R&D programs and external partnerships with an initial focus on diseases with unmet medical needs in immunology and inflammatory diseases.

Further information on Allianthera can be found on LinkedIn: https://www.linkedin.com/company/allianthera–suzhou–biopharmaceutical–co–ltd


About partnering with Dr. Falk Pharma
Dr. Falk Pharma engages in a variety of collaboration and partnership models to develop and deliver innovative treatment concepts with great potential. These treatments can be based on any type of pharmacological approach, from small molecules to biologics to novel drug delivery technologies. The company is involved in partnership projects across the range of phases and partners, from all stages of pre–clinical/clinical development and marketing as well as with academic researchers, start–ups, and established companies.

Dr. Falk Pharma is an industry leader in innovative pharmaceutical formulations that deliver active substances to specific functional segments of the gastrointestinal tract. Many of their products have attained standard–of–care status. The company enjoys strong, long–standing collaborations with renowned clinical centres and with academic and clinical key opinion leaders in the fields of gastroenterology, hepatology and metabolic diseases.

For more information go to https://drfalkpharma.com/en/partnering/


About Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre–clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well–being. A family–owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. Dr. Falk Pharma employs approximately 1400 individuals globally and 340 in Freiburg.

Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com


GLOBENEWSWIRE (Distribution ID 1001120434)

In Syria’s Sectarian Fights for Power, Humanity is the Loser

Amir Saeid Iravani, Permanent Representative of the Islamic Republic of Iran to the United Nations, addresses the Security Council meeting on the situation in the Middle East (Syria). Credit: UN Photo/ Evan Schneider

Amir Saeid Iravani, Permanent Representative of the Islamic Republic of Iran to the United Nations, addresses the Security Council meeting on the situation in the Middle East (Syria). Credit: UN Photo/ Evan Schneider

By Jennifer Xin-Tsu Lin Levine
UNITED NATIONS, Jul 30 2025 – As sectarian violence rises in Syria, the number of displaced people has climbed exponentially since Syrian forces joined clashes between the Druze and Bedouin groups in the Sweida region.

Spokesperson for the Secretary-General Stéphane Dujarric reported in the daily press briefing this Wednesday, “More than 145,000 people have now been displaced due to hostilities in the Suweida governorate.” This marks a rise of over 50,000 people since Monday, when the spokesperson reported 93,000 displaced.

The conflict originated as a dispute between the Druze and Bedouin, two minorities in southern Syria. In Sweida, a Druze-majority city, armed government forces were deployed to quell the violence and regain control of local government structures primarily led by Druze people.

However, after Israel bombed Damascus, citing harms against Druze civilians, Israeli Prime Minister Benjamin Netanyahu outlined a new plan to demilitarize Syrian territory from “south of Damascus and the Golan Heights to the Druze Mountain.”

This decision was widely criticized by global actors, including Secretary-General António Guterres, who called it “essential that these attacks stop and that Israel respect Syria’s sovereignty, unity, territorial integrity, and independence.”

Israel is just one of the many countries involved in Syria’s politics and violence. During the Syrian civil war, a period of general pro-democracy political uprising in the Middle East, countries like Iran and Russia backed the current regime in efforts to prevent further Western influence. Supporting various rebel groups were Turkey, the United States, and Gulf nations like Saudi Arabia and Qatar, each with their own strategic and ideological goals.

As a result, Syria has become a battleground not only for internal factions but also for foreign powers vying for regional influence—often with devastating consequences for the civilian population.

According to the World Health Organization (WHO), over 15.8 million people across Syria were in need of humanitarian assistance as of March 2025, the highest number recorded since the conflict began in 2011. The escalating violence in Sweida further intensifies the crisis and strains an already overstretched aid network.

Medical services have been especially hard-hit. The Euro-Med Human Rights Monitor reported that only 57 percent of hospitals and 37 percent of primary healthcare centers are operating at full capacity, many others struggling due to damaged infrastructure, medicine shortages and the departure of medical personnel.

According to UNDP assessments, there is only one doctor per 2,000 people due to migration over the past decades. Due to the sharp decline in public health spending, these flaws in healthcare infrastructure are particularly glaring in a time when violence has worsened.

However, problems in Syrian infrastructure extend beyond the immediate crisis. UNDP also reported that 30 percent to 50 percent of schools are out of service, damaged, destroyed or repurposed due to war-related destruction or lack of maintenance. Schools that are still operational often do not receive state funding for basic utilities like water, electricity, or heating.

UNICEF has raised alarms about the impact of the conflict on children. The agency estimates that over 2.4 million children are out of school, many of them having been displaced multiple times.

“Years of war and violence have shattered the lives of Syria’s children, with many enduring a lifetime of hardship,” said UNICEF Executive Director Catherine Russell. This has caused stagnation in Syria’s growth—without children to help rebuild infrastructure in education and healthcare, the system remains weakened.

Due to such precarious federal institutions, humanitarian access has similarly lessened. In past years, the UN Security Council has been unable to renew critical cross-border aid mechanisms due to vetoes from permanent members, leaving much of the aid delivery dependent on unstable domestic routes.

In a recent Geneva press briefing, it was confirmed that humanitarian convoys have been delayed or blocked from reaching Sweida and Daraa due to active fighting and lack of security guarantees.

As the power vacuum deepens in Syria, with the central government’s grip weakening and local militias and foreign actors carving out zones of influence, civilians are increasingly left without protection or basic services. The latest violence in Sweida illustrates the high cost of this fragmentation: an already fragile region now overwhelmed by displacement, cut off from aid, and exposed to indiscriminate attacks.

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById({js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);